CRISPR Therapeutics AG (CRSP)
NASDAQ: CRSP · Real-Time Price · USD
47.91
-2.52 (-5.00%)
At close: Feb 21, 2025, 4:00 PM
47.67
-0.24 (-0.50%)
After-hours: Feb 21, 2025, 7:45 PM EST
CRISPR Therapeutics AG Revenue
In the year 2024, CRISPR Therapeutics AG had annual revenue of $37.31M, down -89.95%. CRISPR Therapeutics AG had revenue of $35.69M in the quarter ending December 31, 2024, a decrease of -82.26%.
Revenue (ttm)
$37.31M
Revenue Growth
-89.95%
P/S Ratio
108.31
Revenue / Employee
$94,947
Employees
393
Market Cap
4.11B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 37.31M | -333.89M | -89.95% |
Dec 31, 2023 | 371.21M | 370.01M | 30,885.48% |
Dec 31, 2022 | 1.20M | -913.77M | -99.87% |
Dec 31, 2021 | 914.96M | 914.24M | 127,154.94% |
Dec 31, 2020 | 719.00K | -288.87M | -99.75% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
CRSP News
- 8 days ago - Crispr Therapeutics Q4 Earnings Review: Ignore The Lack Of Revenues, Buy The Future - Seeking Alpha
- 10 days ago - CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results - GlobeNewsWire
- 16 days ago - CRISPR Therapeutics AG (CRSP) Guggenheim SMID Cap Biotech Conference (Transcript) - Seeking Alpha
- 16 days ago - Crispr Therapeutics: Why I've Become Even More Bullish (Rating Upgrade) - Seeking Alpha
- 5 weeks ago - CRISPR Therapeutics: Unfairly Punished By The Issues Of Its Peers - Seeking Alpha
- 5 weeks ago - CRISPR Therapeutics AG (CRSP) 43rd Annual JPMorgan Healthcare Conference - (Transcript) - Seeking Alpha
- 6 weeks ago - CRISPR Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 7 weeks ago - Crispr Therapeutics: From Casgevy Success To A Catalyst-Rich 2025 - Seeking Alpha